Please let me know which of these studies that you are interested in reading, and I will be happy to

hopeful and optimistic

Please let me know which of these studies that you are interested in reading, and I will be happy to post, or you can register to the site, either one is fine with me...I am happy to post the abstracts for any studies that you select

Prostate Cancer ASCO 2013 - Poster: The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer ASCO 2013 - Podcast: The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : A case report - Abstract Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options - Abstract Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? - Abstract Gross hematuria in patients with prostate cancer: Etiology and management - Abstract Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions - Abstract Ultrasonography in prostate cancer: Current roles and potential applications in radiorecurrent disease - Abstract Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer - Abstract Probabilistic objective functions for margin-less IMRT planning - Abstract A knowledge-based approach to improving and homogenizing intensity modulated radiation therapy planning quality among treatment centers: An example application to prostate cancer planning - Abstract Treatment of bladder outlet obstruction in locally advanced prostate cancer - Abstract Treatment of prostate cancer with intermittent versus continuous androgen deprivation: A systematic review of randomized trials - Abstract Managing urine leakage following laparoscopic radical prostatectomy with active suction of the prevesical space - Abstract Prostate cancer magnetic resonance imaging (MRI): Multidisciplinary standpoint - Abstract Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy - Abstract Choline PET/CT for imaging prostate cancer: An update - Abstract ASCO 2013 - Poster: Evidence for a field effect in early prostate cancer (PCa): Gene expression profiles in normal-appearing prostate tissue (NT) adjacent to tumor (T) as predictors of clinical outcome Statin use in relation to prostate cancer outcomes in a population-based patient cohort study - Abstract Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity - Abstract Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening - Abstract ASCO 2013 - Poster: Inhibition of androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone and enzalutamide: a potential mechanism for cross-resistance in castration-resistant prostate cancer ASCO 2013 - Podcast: Inhibition of androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone and enzalutamide: a potential mechanism for cross-resistance in castration-resistant prostate cancer ASCO 2013 - Slide Presentation: Localized and hormone sensitive prostate cancer: Best practices ASCO 2013 - Podcast: Localized and hormone sensitive prostate cancer: Best practices ASCO 2013 - Slide Presentation: Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC) ASCO 2013 - Podcast: Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC) ASCO 2013 - Slide Presentation: Prolaris: A novel genetic test for prostate cancer prognosis ASCO 2013 - Podcast: Prolaris: A novel genetic test for prostate cancer prognosis Radiation therapy for prostate cancer - Abstract A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer - Abstract Life expectancy estimates as a key factor in over-treatment: The case of prostate cancer - Abstract Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death - Abstract Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: A matched cohort analysis - Abstract Vesicocutaneous fistula following adjuvant radiotherapy for prostate cancer - Abstract Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: Analysis of 184 radical prostatectomy specimens - Abstract Prostate brachytherapy: Indications and outcomes - Abstract Intermittent androgen-deprivation therapy in prostate cancer: A critical review focused on phase 3 trials - Abstract The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: A systematic review and meta-analysis - Abstract Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy - Abstract Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL - Abstract Adjuvant radiotherapy or early salvage radiotherapy in pT3R0 or pT3R1 prostate cancer - Abstract Novel imaging techniques reshape the landscape in high-risk prostate cancers - Abstract Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer - Abstract The epidemiology of high-risk prostate cancer - Abstract Consideration of comorbidity in risk stratification prior to prostate biopsy - Abstract Influence of serum prostate-specific antigen (PSA) level, prostate volume, and PSA density on prostate cancer detection with contrast-enhanced sonography using contrast-tuned imaging technology - Abstract An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer - Abstract Salvage CT-guided transgluteal cryoablation for locally recurrent prostate cancer: Initial experiences - Abstract The establishment of K-CaP (the multicenter Korean Prostate Cancer Database) - Abstract Can diffusion-weighted magnetic resonance imaging predict a high Gleason score of prostate cancer? - Abstract Increasing prostate-specific antigen levels differently influence prostate cancer detection rates of two different 12-core prostate biopsy schemes - Abstract Diffusion-weighted magnetic resonance imaging in the prostate transition zone: Histopathological validation using magnetic resonance-guided biopsy specimens - Abstract Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer - Abstract Salvage treatment in prostate cancer: A clinical approach - Abstract Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: Secondary analysis of radiation therapy oncology group (RTOG) 8610 - Abstract Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer - Abstract Active surveillance in low-risk prostate cancer. Patient acceptance and results - Abstract Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: A prospective multi-center study - Abstract Visit the UroToday Prostate Cancer Section

Advanced Prostate Cancer ASCO 2013 - Poster: A randomized, phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer (mCRPC) ASCO 2013 - Poster: Correlation between baseline variables and survival in the radium-223 dichloride phase III ALSYMPCA trial with attention to total ALP changes ASCO 2013 - Podcast: Correlation between baseline variables and survival in the radium-223 dichloride phase III ALSYMPCA trial with attention to total ALP changes ASCO 2013 - Slide Presentation: CRPC: The place of novel agents focused on the androgen axis ASCO 2013 - Podcast: CRPC: The place of novel agents focused on the androgen axis New treatment options for castration-resistant prostate cancer - Abstract ASCO 2013 - Poster: Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011 ASCO 2013 - Poster: Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) ASCO 2013 - Podcast: Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) ASCO 2013 - Poster: Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial ASCO 2013 - Poster: Impact of concomitant bone-targeted therapies on outcomes in metastatic castration-resistant prostate cancer patients without prior chemotherapy treated with abiraterone acetate or prednisone ASCO 2013 - Podcast: Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial ASCO 2013 - Podcast: Impact of concomitant bone-targeted therapies on outcomes in metastatic castration-resistant prostate cancer patients without prior chemotherapy treated with abiraterone acetate or prednisone Visit the UroToday Treatment of (mCRPC) Section

Prostate Cancer Immunotherapy ASCO 2013 - Poster: Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer (BRPC): Immune results AUA 2013 - Cancer immunotherapy: Fundamental concepts and emerging role, urology perspective Slide Lecture: Therapeutic benefit of baseline PSA: Lower baseline PSA is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial ASCO 2013 - Podcast: A discussion of the implementation and sequencing of treatment with sipuleucel-T for men with metastatic castration-resistant prostate cancer (mCRPC): Key messages from poster presentations at ASCO Visit the UroToday Prostate Cancer Immunotherapy Section A message to our readers: During the past 10 years, UroToday has created – and continues to grow – a truly unique and comprehensive database of urologic content. While we pride ourselves in the ability to provide our readers with free access to over 60,000 pages of content, we now require that all guests be registered and logged on before proceeding to our online resources and archive. We invite you to take a moment to register. After that, you may simply log on with your user name and password whenever you visit our site.

UroToday - 2217 Fifth Street - Berkeley, CA 94710 USA Update Your Email Preferences   |   Unsubscribe   |   Forward this Email to a Friend You are receiving this email because you have chosen to receive emails from UroToday.com. Log in to update your email address or view your email preferences. If you have any questions about your account, please log in to contact us securely and we will be happy to assist you.